Please assess the completion status of the following clinical trial:

Trial Title: Sympathetic Nervous System Modulation in Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension with blood pressure less than 140/90 on either an ACE inhibitor or angiotensin receptor blocker~Exclusion Criteria:~* Known valvular heart disease of more than mild severity~* Known coronary artery disease defined by an angiographic coronary artery stenosis greater than or equal to 50% luminal diameter narrowing, acute or previous myocardial infarction, or previous coronary revascularization~* Known non-ischemic cardiomyopathy with left ventricular ejection fraction less than 50%~* Atrial fibrillation~* Current treatment with a β-adrenergic blocking drug or a calcium channel blocker~* Current treatment with a psychoactive or other drug known to alter 123I-MIBG uptake~* Participation in another research study within the prior 30 days~* A life-limiting disease process that is likely to preclude completion of study participation~* Pregnancy or breast feeding~* Inability or unwillingness to provide informed consent~* Baseline resting heart rate less than 65 beats per minute~* Diabetes~* Iodine allergy~* Unwilling to sign informed consent.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- metoprolol succinate (Type: EXPERIMENTAL): Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.

Based on this trial design, predict the completion outcome and termination type (if applicable).